Literature DB >> 17280922

Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain.

Patrick M Dougherty1, Juan P Cata, Allen W Burton, Khanh Vu, Han-Rong Weng.   

Abstract

Vincristine is one of the frontline chemotherapy drugs for the treatment of numerous lymphoid neoplasias. The main dose-limiting complication of vincristine is the development of painful peripheral neuropathy. Although clinical reports have appeared in the literature detailing the symptoms of vincristine neuropathy, quantitative sensory testing data that might yield insight to dysfunction in subsets of primary afferents are lacking. In this report, pain descriptors and anatomical distributions of sensory abnormalities were collected in each patient. Touch detection threshold, sharpness detection threshold, the thresholds for the detection of skin warming, heat pain, skin cooling, and the perception of cooling-induced pain were measured in patients with chronic vincristine-induced pain in each area of sensory abnormality and in skin perceived as outside the affected areas. Elevated touch detection thresholds were observed both within and outside areas affected by pain and sensory abnormality. Elevated sharpness and warm detection thresholds were noted only in areas affected by pain. These data suggest that chronic vincristine-induced pain is associated with dysfunction in Abeta, Adelta, and C caliber primary afferent fibers. Deficits in Abeta fibers appear to precede and presage deficits in the other fiber types, whereas deficits in Adelta- and C-fiber function appear to be specifically associated with the generation of pain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17280922     DOI: 10.1016/j.jpainsymman.2006.08.006

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  46 in total

1.  Cellular and functional evidence for a protective action of neurosteroids against vincristine chemotherapy-induced painful neuropathy.

Authors:  Laurence Meyer; Christine Patte-Mensah; Omar Taleb; Ayikoe Guy Mensah-Nyagan
Journal:  Cell Mol Life Sci       Date:  2010-04-30       Impact factor: 9.261

2.  Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Haijun Zhang; Hongmei Zhang; Alyssa K Kosturakis; Abdul Basit Jawad; Patrick M Dougherty
Journal:  J Pain       Date:  2014-04-19       Impact factor: 5.820

3.  MAPK signaling downstream to TLR4 contributes to paclitaxel-induced peripheral neuropathy.

Authors:  Yan Li; Hongmei Zhang; Alyssa K Kosturakis; Ryan M Cassidy; Haijun Zhang; Ross M Kennamer-Chapman; Abdul Basit Jawad; Cecilia M Colomand; Daniel S Harrison; Patrick M Dougherty
Journal:  Brain Behav Immun       Date:  2015-06-09       Impact factor: 7.217

4.  Antinociceptive effect of matrine on vincristine-induced neuropathic pain model in mice.

Authors:  Dun Linglu; Li Yuxiang; Xu Yaqiong; Zhou Ru; Ma Lin; Jin Shaoju; Du Juan; Sun Tao; Yu Jianqiang
Journal:  Neurol Sci       Date:  2013-12-14       Impact factor: 3.307

5.  Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel.

Authors:  W H Xiao; H Zheng; G J Bennett
Journal:  Neuroscience       Date:  2011-12-20       Impact factor: 3.590

Review 6.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

7.  Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Larry C Driver; Diane M Novy; Brian M Bruel; Deidre L Mooring; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-11       Impact factor: 3.333

Review 8.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

9.  Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Hongmei Zhang; Yan Li; Marianna de Carvalho-Barbosa; Annemieke Kavelaars; Cobi J Heijnen; Phillip J Albrecht; Patrick M Dougherty
Journal:  J Pain       Date:  2016-03-12       Impact factor: 5.820

Review 10.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.